NCT03750188View on ClinicalTrials.gov

Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs

CompletedOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

September 17, 2019

Study Completion Date

October 16, 2019

Conditions
Central Nervous System DiseasesCentral Nervous System Neoplasms
Interventions
DRUG

ProHance

0.1 mmol/kg ProHance intravenous injection

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

Sponsors
All Listed Sponsors
lead

Bracco Diagnostics, Inc

INDUSTRY